Levocabastine (0.25 mg/kg; i.p.; twice a day for five successive days; guinea-pigs) inhibits the virus-induced airway hyperresponsiveness, suppresses the influx of broncho-alveolar cells and increase in albumin content, and corrects the reduced chemiluminescence production by broncho-alveolar cells in response to zymosan.
In mice that receivedβ-LT, Levocabastine (0.05 mg/kg; i.p.) blocks the anxiolytic effect of β-LT and the number of head-dips decreased.